John C Fortney1, Jeffrey M Pyne2, Susan Ward-Jones3, Ian M Bennett1, Joan Diehl4, Kellee Farris5, Joseph M Cerimele1, Geoffrey M Curran6. 1. Division of Population Health, Department of Psychiatry and Behavioral Sciences, University of Washington. 2. Division of Health Services Research, Department of Psychiatry, University of Arkansas for Medical Sciences. 3. East Arkansas Family Health Center. 4. Community Health Centers of Arkansas. 5. Lee County Cooperative Clinic. 6. Center for Implementation Research, Department of Pharmacy Practice, University of Arkansas for Medical Sciences.
Abstract
INTRODUCTION: Use quality improvement methods to implement evidence-based practices for bipolar depression and treatment-resistant depression in 6 Federally Qualified Health Centers. METHOD: Following qualitative needs assessments, implementation teams comprised of front-line providers, patients, and content experts identified, adapted, and adopted evidence-based practices. With external facilitation, onsite clinical champions led the deployment of the evidence-based practices. Evaluation data were collected from 104 patients with probable bipolar disorder or treatment-resistant depression via chart review and an interactive voice response telephone system. RESULTS: Five practices were implemented: (a) screening for bipolar disorder, (b) telepsychiatric consultation, (c) prescribing guidelines, (d) online cognitive-behavioral therapy, and (e) online peer support. Implementation outcomes were as follows: (a) 15% of eligible patients were screened for bipolar disorder (interclinic range = 3%-70%), (b) few engaged in online psychotherapy or peer support, (c) 38% received telepsychiatric consultation (interclinic range = 0%-83%), and (d) 64% of patients with a consult were prescribed the recommended medication. Clinical outcomes were as follows: Of those screening at high risk or very high risk, 67% and 69%, respectively, were diagnosed with bipolar disorder. A third (32%) of patients were prescribed a new mood stabilizer, and 28% were prescribed a new antidepressant. Clinical response (50% reduction in depression symptoms), was observed in 21% of patients at 3-month follow-up. DISCUSSION: Quality improvement processes resulted in the implementation and evaluation of 5 detection and treatment processes. Though varying by site, screening improved detection and a substantial number of patients received consultations and medication adjustments; however, symptom improvement was modest. (PsycINFO Database Record (c) 2018 APA, all rights reserved).
INTRODUCTION: Use quality improvement methods to implement evidence-based practices for bipolar depression and treatment-resistant depression in 6 Federally Qualified Health Centers. METHOD: Following qualitative needs assessments, implementation teams comprised of front-line providers, patients, and content experts identified, adapted, and adopted evidence-based practices. With external facilitation, onsite clinical champions led the deployment of the evidence-based practices. Evaluation data were collected from 104 patients with probable bipolar disorder or treatment-resistant depression via chart review and an interactive voice response telephone system. RESULTS: Five practices were implemented: (a) screening for bipolar disorder, (b) telepsychiatric consultation, (c) prescribing guidelines, (d) online cognitive-behavioral therapy, and (e) online peer support. Implementation outcomes were as follows: (a) 15% of eligible patients were screened for bipolar disorder (interclinic range = 3%-70%), (b) few engaged in online psychotherapy or peer support, (c) 38% received telepsychiatric consultation (interclinic range = 0%-83%), and (d) 64% of patients with a consult were prescribed the recommended medication. Clinical outcomes were as follows: Of those screening at high risk or very high risk, 67% and 69%, respectively, were diagnosed with bipolar disorder. A third (32%) of patients were prescribed a new mood stabilizer, and 28% were prescribed a new antidepressant. Clinical response (50% reduction in depression symptoms), was observed in 21% of patients at 3-month follow-up. DISCUSSION: Quality improvement processes resulted in the implementation and evaluation of 5 detection and treatment processes. Though varying by site, screening improved detection and a substantial number of patients received consultations and medication adjustments; however, symptom improvement was modest. (PsycINFO Database Record (c) 2018 APA, all rights reserved).
Authors: C L Bowden; R H Perlis; M E Thase; T A Ketter; M M Ostacher; J R Calabrese; N A Reilly-Harrington; J M Gonzalez; V Singh; A A Nierenberg; G S Sachs Journal: CNS Neurosci Ther Date: 2011-06-07 Impact factor: 5.243
Authors: Amar K Das; Mark Olfson; Marc J Gameroff; Daniel J Pilowsky; Carlos Blanco; Adriana Feder; Raz Gross; Yuval Neria; Rafael Lantigua; Steven Shea; Myrna M Weissman Journal: JAMA Date: 2005-02-23 Impact factor: 56.272
Authors: Ronald C Kessler; Hagop S Akiskal; Jules Angst; Margaret Guyer; Robert M A Hirschfeld; Kathleen R Merikangas; Paul E Stang Journal: J Affect Disord Date: 2006-09-25 Impact factor: 4.839
Authors: Jürgen Unützer; Ya-Fen Chan; Erin Hafer; Jessica Knaster; Anne Shields; Diane Powers; Richard C Veith Journal: Am J Public Health Date: 2012-04-19 Impact factor: 9.308
Authors: Isabella Pacchiarotti; David J Bond; Ross J Baldessarini; Willem A Nolen; Heinz Grunze; Rasmus W Licht; Robert M Post; Michael Berk; Guy M Goodwin; Gary S Sachs; Leonardo Tondo; Robert L Findling; Eric A Youngstrom; Mauricio Tohen; Juan Undurraga; Ana González-Pinto; Joseph F Goldberg; Ayşegül Yildiz; Lori L Altshuler; Joseph R Calabrese; Philip B Mitchell; Michael E Thase; Athanasios Koukopoulos; Francesc Colom; Mark A Frye; Gin S Malhi; Konstantinos N Fountoulakis; Gustavo Vázquez; Roy H Perlis; Terence A Ketter; Frederick Cassidy; Hagop Akiskal; Jean-Michel Azorin; Marc Valentí; Diego Hidalgo Mazzei; Beny Lafer; Tadafumi Kato; Lorenzo Mazzarini; Anabel Martínez-Aran; Gordon Parker; Daniel Souery; Ayşegül Ozerdem; Susan L McElroy; Paolo Girardi; Michael Bauer; Lakshmi N Yatham; Carlos A Zarate; Andrew A Nierenberg; Boris Birmaher; Shigenobu Kanba; Rif S El-Mallakh; Alessandro Serretti; Zoltan Rihmer; Allan H Young; Georgios D Kotzalidis; Glenda M MacQueen; Charles L Bowden; S Nassir Ghaemi; Carlos Lopez-Jaramillo; Janusz Rybakowski; Kyooseob Ha; Giulio Perugi; Siegfried Kasper; Jay D Amsterdam; Robert M Hirschfeld; Flávio Kapczinski; Eduard Vieta Journal: Am J Psychiatry Date: 2013-11 Impact factor: 18.112
Authors: Susanne Hempel; Maria Bolshakova; Barbara J Turner; Jennifer Dinalo; Danielle Rose; Aneesa Motala; Ning Fu; Chase G Clemesha; Lisa Rubenstein; Susan Stockdale Journal: J Gen Intern Med Date: 2022-09-29 Impact factor: 6.473
Authors: David J Kolko; Elizabeth A McGuier; Renee Turchi; Eileen Thompson; Satish Iyengar; Shawna N Smith; Kimberly Hoagwood; Celeste Liebrecht; Ian M Bennett; Byron J Powell; Kelly Kelleher; Maria Silva; Amy M Kilbourne Journal: Implement Sci Date: 2022-02-22 Impact factor: 7.960
Authors: Kelly A Aschbrenner; Gina Kruse; Karen M Emmons; Deepinder Singh; Marjanna E Barber-Dubois; Angela M Miller; Annette N Thomas; Stephen J Bartels Journal: Prev Sci Date: 2022-10-04
Authors: Margie E Snyder; Betty Chewning; David Kreling; Susan M Perkins; Lyndee M Knox; Omolola A Adeoye-Olatunde; Heather A Jaynes; Jon C Schommer; Matthew M Murawski; Nisaratana Sangasubana; Lisa A Hillman; Geoffrey M Curran Journal: Res Social Adm Pharm Date: 2020-04-24